# Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

> **NCT03828084** · PHASE1 · COMPLETED · sponsor: **EpiDestiny, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT03828084
- **Lead sponsor:** EpiDestiny, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-03
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828084, "Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03828084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*